Position in EXEL
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$1,639,899
-$1,360,615 QoQ
Shares Held
38,235
-44.1% QoQ
Ownership
0.015%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2022
8 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Grantham, Mayo, Van Otterloo & Co. LLC holds $93,420,610 across 9 Biotechnology names. EXEL ranks #4 (1.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
55,353 | $42,767,941 | |
| 2 | INCY |
Incyte Corp
|
364,657 | $34,321,516 | |
| 3 | FOLD |
AMICUS THERAPEUTICS, INC.
|
941,266 | $13,610,706 | |
| 4 | EXEL |
Exelixis, Inc.
This page
|
38,235 | $1,639,899 | |
| 5 | ALT |
Altimmune, Inc.
|
126,389 | $389,278 | |
| 6 | HRMY |
Harmony Biosciences Holdings, Inc.
|
11,182 | $313,207 | |
| 7 | RNA |
Atrium Therapeutics, Inc.
|
15,444 | $206,486 | |
| 8 | VNDA |
Vanda Pharmaceuticals Inc.
|
16,322 | $112,785 |
All Filings in EXEL
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,639,899 | 38,235 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $3,000,514 | 68,458 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $489,363 | 11,849 | Shares | Sole | 2025-11-13 | |
| 2024-12-31 | $5,033,394 | 151,153 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $2,177,127 | 83,897 | Shares | Sole | 2024-11-13 | |
| 2022-12-31 | $1,557,484 | 97,100 | Shares | Sole | 2023-02-13 | |
| 2022-09-30 | $343,392 | 21,900 | Shares | Sole | 2022-11-10 | |
| 2022-06-30 | $376,842 | 18,100 | Shares | Sole | 2022-08-12 | |
| No filing history on record for this holder in this stock. | ||||||